SA
Log In
RVMD
OverviewIntelligenceChart
Signal
Bullish Setup2↑
Price
1↑
Move↑+1.65%Positive session
Volume
1→
Volume↓0.0× avgLight volume
Technical
1↑
RSI↑RSI 67Momentum positive
PRICE
Prev Close
147.21
Open
146.87
Day Range145.38 – 150.45
145.38
150.45
52W Range34.00 – 155.70
34.00
155.70
95% of range
VOLUME & SIZE
Avg Volume
3.1M
FUNDAMENTALS
P/E Ratio
-24.7x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.48
Market-like
Quick Read
Trend—Insufficient MA data
Momentum
BEARISH
thin 0% gross margin
Valuation
FAIR
P/E not available
Health
MODERATE
CR 7.1 · FCF negative
Neutral
Key MetricsTTM
Market Cap$31.82B
Revenue TTM$0.00
Net Income TTM-$1.13B
Free Cash Flow-$913.73M
Gross Margin0.0%
Net Margin0.0%
Operating Margin0.0%
Return on Equity-63.1%
Return on Assets-48.0%
Debt / Equity0.10
Current Ratio7.14
EPS TTM$-5.95
Alpha SignalsView Intelligence →

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
2 strong1 watch3 concern
42/100
Liquidity
7.14Strong
Leverage
0.10Strong
Coverage
-50.6xConcern
ROE
-63.1%Concern
ROIC
-56.8%Concern
Cash
$384MWatch
ANALYST COVERAGE22 analysts
BUY
▲ +9.3%upside to target
L $73.00
Med $163.50consensus
H $200.00
Strong Buy
15%
Buy
2091%
Hold
15%
21 Buy (95%)1 Hold (5%)0 Sell (0%)
Full report →
Stock Health
Composite Score
3 of 4 signals bullish
8/10
Technicals
●
RSI RangeRSI 67 — Bullish momentum
✓
Fundamentals
●
Last EarningsMissed estimates
✗
●
Analyst ConsensusBuy
✓
●
LiquidityCurrent Ratio 7.14 — healthy liquidity
✓

1 signal unavailable — limited data for this stock

Upcoming Events
EEarnings ReportMay 7, 2026
Tomorrow
DEx-Dividend DateAug 4, 2026
In 90 days
PDividend PaymentAug 13, 2026
In 99 days
Research
Fundamentals→Financials→Analysts→Earnings→Growth→Key Metrics→Technical Analysis→Intelligence→
Technicals
Technical SetupBULLISH
Technicals →

Trend

▲ UptrendGolden Cross · 50D leads 200D by 46.3%

+37.3% vs SMA 50 · +100.8% vs SMA 200

Momentum

RSI67.0
Positive momentum, not extended
MACD+11.29
Above zero — bullish momentum · expanding
Market Position
Price Levels
52W High
$155.7+4.0%
Current
$149.6
EMA 50
$115.3-22.9%
EMA 200
$78.53-47.5%
52W Low
$34.00-77.3%
52-Week RangeNear 52-week high
$34.0095th %ile$155.7
Earnings & Analysts

ANALYST ESTIMATES

Consensus of 17 analysts
Full estimates →
Analyst revisions:EPS↑ Revised UpRevenue↓ Revised Down

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$3.5M
$678742–$6.3M
—-$5.65—
±5%
High15
FY2026(current)
$77.1M
$8.2M–$177.1M
▲ +2111.7%-$7.55—
±14%
High17
FY2027
$600.3M
$131.7M–$1.8B
▲ +679.0%-$5.71—
±50%
High14
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryRVMD
Last 8Q
-10.8%avg beat
Beat 1 of 8 quartersMissed 7↓ Estimates falling
+6%
Q2'24
-5%
Q3'24
-5%
Q4'24
-11%
Q1'25
-1%
Q2'25
-39%
Q3'25
-13%
Q4'25
-18%
Q1'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Analyst Activity
All ratings →
No recent activity
Piper SandlerOverweight → Neutral
Jul 16
DOWNGRADE
Raymond JamesStrong Buy
Apr 10
UPGRADE
Bank of America Sec…Buy
Jan 5
UPGRADE
Morgan StanleyEqual-Weight
Feb 28
DOWNGRADE
William BlairMarket Perform
Feb 28
DOWNGRADE
Goldman SachsSell
Feb 28
DOWNGRADE
Piper SandlerOverweight
Feb 28
UPGRADE
Insider Activity
SEC Filings →
0 Buys/6 SellsNet Selling
NET SELLERS$0 bought · $18.4M sold · 30d window
Mancini AnthonySee Remarks
$220K
Apr 27
SELL
Mancini AnthonySee Remarks
$139K
Apr 27
SELL
Mancini AnthonySee Remarks
$54K
Apr 27
SELL
Goldsmith Mark ADir
$18.0M
Apr 15
SELL
Mancini AnthonySee Remarks
$168K
Mar 25
SELL
Mancini AnthonySee Remarks
$295K
Mar 25
SELL
Financials

INSTITUTIONAL OWNERSHIP

13-F Filings →
1
UBS Group AG
4.4M▲
2
Bank of New York Mellon Corp
635K▲
3
Candriam S.C.A.
581K▼
4
Pictet Asset Management Holding SA
558K▼
5
Lunate Capital Ltd
549K▼
6
Mass General Brigham, Inc
344K—
7
Nuveen, LLC
341K▼
8
Sumitomo Mitsui Trust Holdings, Inc.
271K▲
News & Activity

RVMD News

20 articles · 4h ago

About

revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.

Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Mark Goldsmith
Website
revolutionmedicines.com ↗
Stephen Kelsey Path. FRCPPresident of Research & Development
Mark A. GoldsmithChief Executive Officer, President & Chairman
Jeff CisliniSenior Vice President, General Counsel & Corporate Secretary

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance